Low Dose IL-2 Efficacy in Rheumatoid Arthritis
A novel biologic intervention trial has shown that subcutaneous, intermittent therapy with low-dose interleukin-2 (Ld-IL2) is potentially effective and safe in rheumatoid arthritis (RA).
News
Efficacy and Safety of Mavrilimumab in Giant Cell Arteritis
A phase II trial in patients with active giant cell arteritis shows that mavrilimumab, a monoclonal antibody against granulocyte-macrophage colony-stimulating factor [GM-CSF]) is capable of inducing clinical remission.
Predicting Spondylitis in At-Risk Relatives
The risk of developing axial spondyloarthritis (axSpA) if you’re a first-degree relative (FDRs) of an ankylosing spondylitis (AS) patient has been deflined by a 35 year follow-up study showing that if you are a FDR of axSpA you may be at higher risk of acute anterior uveitis (AAU).
RheumNow Live is Coming to Town (3.11.2022)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Psoriatic Arthritis Responds to Tyk2 inhibition with Deucravacitinib
Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe.
Could Anifrolumab Work in Lupus Nephritis?
Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit.
Kawasaki Disease Guideline from ACR and Vasculitis Foundation
ACR
The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released a new guideline for the management of Kawasaki disease that addresses diagnostic issues relating to Kawasaki disease, the treatment of high-risk patients, and the management of
Combo MTX and Leflunomide in Psoriatic Arthritis
A recent study has shown that the combination of methotrexate (MTX) plus leflunomide (LEF) yields better disease control in psoriatic arthritis, but may not be as well tolerated as monotherapy with MTX.
Baricitinib’s COVID-19 Efficacy in the RECOVERY Trial
Pre-print results of the RECOVERY Trial has shown that when baricitinib (BAR) is given to hospitalized severe COVID-19 patients, it results in significantly less mortality.
Failed Osteoarthritis Pulse Ultrasound Study
MedPage Today
A promising therapy aimed at halting and even reversing the pathology underlying osteoarthritis (OA) of the knee failed to show any benefit in a randomized trial.
Ethnic and Behavioral Drivers of Gout Risk
Gout is common but disproportionately affects certain groups (e.g., the elderly, Pacific Islander, Blacks). Ethnic links to gouts were also shown to be linked to modifiable behavioral factors and such information maybe useful in managing gout patients.
Undifferentiated Arthritis Does Not Follow an RA Course
Undifferentiated arthritis (UA) is common in medical practice and many advocate early use of DMARDs; yet a recent study shows that despite DMARD use, UA patients do not fair well with this approach.
